A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer
A Observational RWS of YWBC on the Prognosis and Treatment
This is a multicenter, open and observational real world study. The main purpose of this study is to map the genomic variation map of young breast cancer patients in China, and to analyze the relationship between gene mutation and therapeutic effect of young breast cancer patients. The secondary purpose was to analyze the relationship between gene mutation and prognosis of young breast cancer patients.
We expect to enroll 2000 young breast cancer patients (≤35 years old). All patients were detected by targeted next generation sequencing （NGS）(600+ gene panel). Clinical diagnosis, treatment and prognosis information were collected. The Stratification factors mainly include stage, molecular type and treatment method.
연구 개요
상태
정황
상세 설명
The study can only be formally carried out with the written approval of the ethics committee. We regularly submit annual research reports to the ethics committee. We will inform the ethics committee in writing when the study is discontinued and / or completed.
All patients were required to sign informed consent before entering the group. All updated versions of informed consent and written information will be provided to the subjects during the participant's participation.
In the experimental design stage, the statistical principle was used to make reasonable and effective arrangements for the relevant factors. Employ statistical experts to calculate the sample size and data statistics, and participate in the design process. Data collection and follow-up were conducted by specially assigned personnel, professional doctors were assigned to conduct data review regularly, and special data management personnel were provided. They will ensure the authenticity, reliability and security of data throughout the process.
연구 유형
등록 (예상)
연락처 및 위치
연구 장소
-
-
-
Tianjin, 중국, 300060
- 모병
- Tianjin Medical University Cancer Institute and Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
We expect to enroll 2000 young breast cancer patients (18-35 years old). All patients were detected by targeted next generation sequencing （NGS）(600+ gene panel).
Subgroups were stratified according to different stages, treatment methods and pathological types.
The gene mutation characteristics, treatment sensitive genes and prognosis gene spectrum of different groups and subgroups were studied.
설명
Inclusion Criteria:
- Histologically confirmed as breast cancer.
- The age of diagnosis was 18-35 years old.
- ECOG score was 0-2, and the expected survival time was more than 3 months.
- No serious complications; no liver, kidney, hematopoiesis dysfunction.
- Informed consent, and patients willing to long-term follow-up. -
Exclusion Criteria:
- 4 weeks before the start of the study, the use of drugs other than the trial, or participate in another clinical study at the same time, or others with an impact on the results of this study.
- Having a clear history of neurological or mental disorders (including epilepsy or dementia).
- Patients have uncontrollable complications, including active infection, symptomatic congestive heart failure, unstable angina pectoris, arrhythmia, decompensated diabetes, uncontrollable hypertension or mental disorders.
- Pregnant or lactating female patients.
- HIV infected patients.
- Patients with other tumors.
- After comprehensive evaluation, the researchers believe that patients are not suitable for this study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PFS
기간: 5 years
|
The time from the first medication at the beginning of treatment to the first disease progression or death from any cause
|
5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
OS
기간: 5 years
|
time from randomization to death from any cause
|
5 years
|
|
ORR
기간: 5 years
|
After treatment, the percentage of patients whose tumor volume reduced to a predetermined value and could maintain the minimum time limit was evaluated, including complete remission (CR) + partial remission (PR)
|
5 years
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
AEs
기간: 5 years
|
It refers to any adverse medical event during the clinical study.
It is not necessarily a causal relationship with treatment.
|
5 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- YWBC-001
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .